The Coin Toss of Psychosis Risk
Psychedelics and Psychosis Risk: Understanding Gender and Age Differences
The concept of the “never-ending trip” persists in psychedelic lore, fueled by fears that a psychedelic experience could trigger a lifelong psychotic break. This myth largely stems from sensationalized media coverage during the 1960s when psychedelics were criminalized. While these fears remain part of collective consciousness, the scientific understanding of psychosis risk is still developing. The psychosis continuum—recognizing that psychosis exists along a spectrum—was only introduced in the 1990s.
Some individuals do have higher lifetime risk for psychosis, a concept known as psychosis proneness. Recognizing this continuum is crucial for building a responsible, informed psychedelic science, particularly as psychedelics gain traction as potential therapies. Women over 45 may represent a higher-risk group due to hormonal changes, highlighting the need for targeted research to ensure safe psychedelic experiences.
Psychosis-Proneness–Persistence–Impairment Model
The psychosis-proneness–persistence–impairment model theorizes that psychosis exists on a continuum. Healthy individuals can experience temporary psychotic experiences (PEs) without clinical intervention [1].
Prevalence: Lifetime prevalence of PEs is roughly 5% in the general population [2,3].
Transience: Approximately 75–90% of PEs are transitory and resolve over time [3].
Phenotypes: PEs are categorized as positive, depressive, or negative [4].
Clinical Progression: Persistent subclinical PEs may lead to clinical psychosis. In an 8-year cohort study, 38.3% of participants who developed clinical psychosis had at least one prior PE, and 19.6% had multiple [5].
Understanding psychosis proneness can help identify environmental risk factors, improve early detection, and inform safe psychedelic practices [6,7].
Gender and Age Differences in Psychosis Risk
Traditionally, late-adolescent males have been considered the highest-risk group for psychosis [8,9]. However, recent research shows that first-onset psychosis after age 40 is more common than previously recognized [10-12]. Notably, 66–87% of late-onset cases are women [13].
Large epidemiological studies often exclude women over 45, creating a gender and age bias in psychosis research [14]. Female-only data reveal a second peak of first-time psychosis between ages 45–55, likely linked to menopause-related hormonal changes [15-17].
Menopause and Psychosis Vulnerability
The menopausal transition marks the end of reproductive years and involves declining oestrogen levels, disrupting menstrual cycles [18]. Menopause can lead to:
Psychological symptoms: anxiety, depression
Physiological symptoms: sleep disturbances, hot flashes
Neurocognitive changes: altered cerebral blood flow and metabolism [19-21]
Animal models suggest menopause-related neurobiological changes increase vulnerability to psychosis by affecting dopamine sensitivity, a key factor in psychosis and a receptor pathway targeted by psychedelics (5-HT2A/B) [22-23].
Oestrogen, Psychedelics, and Psychosis Risk
Declining oestradiol levels are associated with psychiatric symptoms due to disruption of the mesolimbic reward system, potentially triggering psychosis [24]. Treatment with oestradiol has been shown to:
Reduce psychotic symptoms in postmenopausal women [25,26]
Alleviate postpartum psychosis [27,28]
Reduce menopause-related symptoms [29-31]
Oestrogen modulates 5-HT2A receptors, which are also activated by psychedelics [32]. This overlap suggests that psychedelics may offer unique therapeutic benefits for menopausal women, but could also increase psychosis risk. Activation of dopaminergic pathways via psychedelics may lead to overactivation of 5-HT2A receptors, potentially triggering psychosis [34].
Knowledge Gaps and the Need for Research
Currently, the relationship between female-specific psychosis risk and psychedelic use is underexplored. Understanding these factors is essential to:
Reduce risk of psychosis
Provide early prevention strategies
Inform safe psychedelic use among women over 40
Enable informed health decisions
Awareness of personal psychosis risk has been shown to improve quality of life, making it imperative to extend this knowledge to female populations in midlife.
References
Linscott RJ, van Os J. Psychological Medicine. 2013;43(6):1133-49.
McGrath JJ et al. JAMA Psychiatry. 2015;72(7):697-705.
van Os J, Linscott RJ. Psychol Med. 2009;39(2):179-95.
Stefanis NC et al. Psychol Med. 2002;32(2):347-58.
Dominguez MDG et al. Schizophr Bull. 2009;37(1):84-93.
Rietdijk J et al. Schizophr Res. 2011;132(2-3):213-9.
Cougnard A et al. Psychol Med. 2007;37(4):513-27.
Barajas A et al. Sci World J. 2015;430735.
Solmi M et al. Mol Psychiatry. 2022;27(1):281-95.
Howard R et al. Am J Psychiatry. 2000;157(2):172-8.
Howard R et al. Br J Psychiatry. 1993;163(3):352-7.
Breitner JCS. Arch Gen Psychiatry. 2002;59(1):60-1.
Li R et al. J Transl Neurosci. 2016;1(1):37.
Häfner H. Psychiatry J. 2019;2019:9804836.
Häfner H et al. Schizophr Bull. 1998;24(1):99-113.
Häfner H. Psychiatry J. 2019;2019.
Fisher VL et al. Front Psychiatry. 2022;13:906796.
Buckler H. Br Menopause Soc J. 2005;11(2):61-5.
Bruce D, Rymer J. Best Pract Res Clin Obstet Gynaecol. 2009;23(1):25-32.
del Prado Aa M et al. Rev Méd Chile. 2008;136:1511-7.
Hogervorst E et al. Best Pract Res Clin Obstet Gynaecol. 2022;81:69-84.
Arad M, Weiner I. Neuropsychopharmacology. 2010;35(7):1570-82.
Conn K-A et al. Front Neurosci. 2020;14:542.
Walsh MJ et al. Trials. 2023;24(1):150.
Kulkarni J et al. Arch Gen Psychiatry. 2008;65(8):955-60.
Yu N-W et al. Taiwan J Psychiatry. 2010;24(2).
Ahokas A et al. J Clin Psychiatry. 2000;61(3):166-9.
Maguire J et al. Handb Clin Neurol. 2020;171:97-116.
Cintron D et al. Endocrine. 2017;55:702-11.
Salpeter S et al. Diabetes Obes Metab. 2006;8(5):538-54.
Cardozo L et al. Obstet Gynecol. 1998;92(4):722-7.
Michalska da Rocha B et al. Schizophr Bull. 2017;44(1):114-25.
Bauer BE. Female Hormones, 5-HT2A Receptors, and Psychedelics.
Wischhof L, Koch M. Behav Pharmacol. 2016;27(1):1-11.